Dirk Jan A R Moes
Overview
Explore the profile of Dirk Jan A R Moes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
766
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hanrath M, Banken E, van den Wildenberg S, van de Kerkhof D, Moes D, Boisdron-Celle M, et al.
Cancer Chemother Pharmacol
. 2025 Feb;
95(1):34.
PMID: 39955449
Purpose: In 20-30% of the patients, fluoropyrimidines (5-FU) based chemotherapy leads to severe toxicity, which is associated with dihydropyridine dehydrogenase (DPD) deficiency. Therefore, DPYD genotyping became standard practice before treatment...
2.
Rudesheim S, Loer H, Feick D, Marok F, Fuhr L, Selzer D, et al.
Clin Pharmacol Ther
. 2025 Feb;
PMID: 39953671
Conducting clinical studies on drug-drug-gene interactions (DDGIs) and extrapolating the findings into clinical dose recommendations is challenging due to the high complexity of these interactions. Here, physiologically-based pharmacokinetic (PBPK) modeling...
3.
Shadid I, Brustad N, Chawes B, Moes D, Weiss S, Guchelaar H, et al.
Biomed Pharmacother
. 2025 Jan;
183:117859.
PMID: 39874780
Gestational 25-hydroxyvitamin D (25[OH]D) is important in fetal lung development and may influence offspring respiratory outcomes, making accurate exposure assessment essential to understand clinical associations. Therefore, we used the combined...
4.
Yin A, de Groot F, Guchelaar H, Nijland M, Doorduijn J, Touw D, et al.
Clin Pharmacokinet
. 2024 Dec;
64(1):79-91.
PMID: 39625585
Background: High-dose methotrexate (HD-MTX)-based polychemotherapy is widely used for patients with central nervous system (CNS) lymphoma. The pharmacokinetic (PK) variability and unpredictable occurrence of toxicity remain major concerns in HD-MTX...
5.
Masuda S, Lemaitre F, Barten M, Bergan S, Shipkova M, van Gelder T, et al.
Ther Drug Monit
. 2024 Sep;
47(1):4-31.
PMID: 39331837
The Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology established the second consensus report to guide therapeutic drug monitoring (TDM) of everolimus (EVR)...
6.
Leegwater E, Baidjoe L, Wilms E, Visser L, Touw D, de Winter B, et al.
Clin Pharmacol Ther
. 2024 Aug;
117(1):184-192.
PMID: 39148353
The goal of the study was to describe the population pharmacokinetics of trimethoprim, sulfamethoxazole, and N-acetyl sulfamethoxazole in hospitalized patients. Furthermore, this study used the model to optimize dosing regimens...
7.
Meertens M, Giraud E, van der Kleij M, Westerdijk K, Guchelaar N, Bleckman R, et al.
Clin Pharmacokinet
. 2024 Jul;
63(7):1045-1054.
PMID: 39012619
Introduction And Objective: Pazopanib is registered for metastatic renal cell carcinoma and soft-tissue sarcoma (STS). Its variable pharmacokinetic (PK) characteristics and narrow therapeutic range provide a strong rationale for therapeutic...
8.
In t Veld A, Eveleens Maarse B, Juachon M, Meziyerh S, de Vries A, van Rijn A, et al.
Clin Transl Sci
. 2024 Jun;
17(6):e13860.
PMID: 38923308
The recommended immunosuppressive treatment after kidney transplantation consists of tacrolimus, mycophenolate mofetil, and low-dose corticosteroids. Drug concentrations are monitored using therapeutic drug monitoring (TDM), which does not necessarily correlate with...
9.
Tan Z, Voller S, Yin A, Rieborn A, Gelderblom A, van der Hulle T, et al.
Clin Pharmacokinet
. 2024 Jun;
63(6):857-869.
PMID: 38874883
Introduction: Cabozantinib is one of the preferred treatment options in the latest metastatic renal cell carcinoma (mRCC) guidelines. Cabozantinib is also associated with high drug expenses irrespective of the used...
10.
van Gelder T, Gelinck A, Meziyerh S, de Vries A, Moes D
Br J Clin Pharmacol
. 2024 Jun;
PMID: 38844792
Measurement of pre-dose tacrolimus concentrations, also referred to as trough concentrations or C0 (in this paper the term C0 will be used), is the most frequently used parameter for therapeutic...